Mark Litzow, MD- Hematologist, Oncologist, Palliative Care Specialist- Mayo Clinic
In a presentation delivered by Mark Litzow, MD, the speaker expresses gratitude for the invitation and acknowledges the organizers. The speaker humorously remarks that they are unsure who needs transplants nowadays. They express their intention to address the question of who needs transplantation in the first remission (CR1) and highlight the importance of relapse and its relation to transplant outcomes.
Dr. Litzow outlines the presentation’s objectives and briefly discusses topics such as pediatric intensive regimens, immunotherapy, and targeted therapy for pH-positive acute lymphoblastic leukemia (ALL). He mentions studies showing the benefits of pediatric regimens for adolescents and young adults and discusses the role of minimal residual disease (MRD) assessment and oncogenetics in predicting outcomes. The presentation covers CAR T cell therapy and debates whether it can replace transplants for patients in remission.